Trending Clinical Issues Influencing HIV Practice Today
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M, Orkin C, Podzamczer D, et al. Lancet HIV. 2019;6(9):e576-e587.
Bositis CM, St. Louis J. Infect Dis Clin North Am. 2019;33(3):835-855.
Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials.
Cahn P, Madero JS, Arribas JR, et al. J Acquir Immune Defic Syndr. 2020;83(3):310-318.
Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States.
Colasanti J, Sumitani J, Mehta CC, et al. Open Forum Infect Dis. 2018;5(6):ofy104.
Eisinger RW, Dieffenbach CW, Fauci AS. JAMA. 2019;321(5):451-452.
Hagins DP, Kumar PN, Saag M, et al. Conference on Retroviruses and Opportunistic Infections (CROI); March 8-11, 2020; Boston, MA. Abstract 36.
Linkage and antiretroviral therapy within 72 hours at a Federally Qualified Health Center in New Orleans.
Halperin J, Butler I, Connor K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.
Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT Trial.
Johnson M, Kumar P, Molina JM, et al; for the DRIVE-SHIFT Study Group. J Acquir Immune Defic Syndr. 2019;81(4):463-472.
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM, Ward D, Brar I, et al. Lancet HIV. 2018;5(7):e357-e365.
Nanni MG, Caruso R, Mitchell AJ, et al. Curr Psychiatry Rep. 2015;17(1):530.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.
The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.
Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.
Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.
Sax PE, Erlandson KM, Lake JE, et al. Clin Infect Dis. 2020;71(6):1379-1389.
Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV.
Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Clin Infect Dis. 2020. [Epub ahead of print].
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.
Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO Study.
van Wyk J, Ajana F, Bisshop F, et al. Clin Infect Dis. 2020. [Epub ahead of print].
Zash R, Holmes L, Diseko M, et al. J Int AIDS Soc. 2020;23(suppl 4):183-184. Abstract OAXLB0102.
Testing your Knowledge
Can a Shift to Rapid-ART Get Us There?
An Online and Mobile Mini-Curriculum
Where Will 2-Drug Regimens and Long-Acting Agents Fit?
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCPs Role in Preventing HIV
The PCP’s Role in Timely Recognition and Referral
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
Maximizing Your Role to Impact Patient Outcomes
Benefits, Barriers, & Best Practices in an Advancing Field